Morning Summary - Jul 13 2026

Research evidence excerpt

Morning Summary - Jul 13 2026

MORNING SUMMARY

July 13, 2026

INITIATION OF COVERAGE

BRIGHTSPRING HEALTH SERVICES, INC. Buy

BTSG: This Rocket Can Reach Beyond The Moon – Initiate With a

Buy Rating and $81 PT BTSG $71.43 Price$81.00TargetJason Cassorla

212 518 9501, jason.cassorla@guggenheimpartners.com

Current Q Next Q Current FY Next FY

CLICK HERE TO ACCESS THIS REPORT

$193 $204 $809 $952

Published on July 13, 2026

Market Cap (M) Metric Mult Curr Yr. Mult Next Yr.

$13,852 EBITDA($M) - -

Key Message: We are initiating coverage of BrightSpring Health Services, Inc. (BTSG) with a Buy rating and $81 price target. As an independent leader of

home- and community-based pharmacy and medical care services, BTSG is well positioned to capitalize on a plethora of secular tailwinds within healthcare.

The company’s best-in-class specialty Rx platform combined with an industry undergoing robust pharmacological innovation, tailored offerings for clinically

complex patient populations, and the ever-rising demand for care delivered at lower-cost settings, all support an accelerated organic growth construct over

a multi-year horizon, in our view. This paradigm is further augmented by its improved capital position following its Community Living divestiture, which layers

in inorganic and other shareholder-friendly opportunities. Hefty valuation against this >mid-teens% EBITDA growth outlook is likely to be a point of contest,

but earnings upside opportunity generated from what we dub BTSG’s “rocket” growth engine against reasonable, but elevated expectations, supports our

constructive view of the stock.

PRICE TARGET CHANGES

ELI LILLY AND COMPANY Buy

LLY: Pre-2Q26 Model Update; Anticipation of Beat-And-Raise With